Looking at the trials of Crestor, the statin made by AstraZeneca, Topol estimates that there’s something like a one in 200 risk of getting diabetes on a statin, while only two in 200 heart attacks, heart surgeries, or other types of heart problems will be prevented. The benefits don’t really outweigh the risks for all patients, he argues, and those who are taking the high-powered statins might want to consider a lower dose or even stopping the drugs altogether.
via forbes.com
No comments:
Post a Comment